Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc AGNPF


Primary Symbol: C.AGN

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by C10H12N2on Feb 07, 2023 12:14pm
88 Views
Post# 35272018

RE:RE:AGN.c upcoming milestones

RE:RE:AGN.c upcoming milestonesWithout an uplist to NASDAQ this stock will most likely remain in the gutter. People want to see data and uplist ro NASDAQ. They have been royally screwed with the 100 to 1 reverse spilit based on an uplist that never happened. In the meantime, your leaders allowed AlphaNorth (a small investment outfit) to gobble up 13% of the company which disqualifies Algernon from uplisting to NASDAQ for the foreseeable future. Algernon cannot be taken seriously. Hence, they moved the DMT angle out from under shareholders feet assuming newbies who don't follow penny world stocks will not understand how your leadership has operated in the past. It's an attempt to whitewash their ongoing mistakes, mismanagement and mishaps since Christopher Moreau took the helm back in eary 2018. It's been nothing but downhill every since. Period.
<< Previous
Bullboard Posts
Next >>